06/26/2017

NCCN has published updates to the NCCN Guidelines® and the NCCN Compendium® for Non-Small Cell Lung Cancer

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Non-Small Cell Lung Cancer. These NCCN Guidelines^® are currently available as Version 7.2017. 

• Metastatic Disease – ALK Rearrangement Positive
  • First-line Therapy (NSCL-20)
    • ALK rearrangement discovered prior to first-line chemotherapy: Alectinib added as a category 1, preferred treatment option.
    • ALK rearrangement discovered during first-line chemotherapy: Complete planned chemotherapy, including maintenance therapy, or interrupt, followed by alectinib or crizotinib or ceritinib.
  • Subsequent Therapy (NSCL-21)
    • Asymptomatic, Brain, and Systemic isolated lesions: "continue alectinib" added as a treatment option..

• The Discussion section has been updated to reflect the changes in the algorithm. 

*For your reference, the previous update (Version 6.2017) to the NCCN Guidelines for Non-Small Cell Lung Cancer, published on May 12, 2017, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf